We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > brensocatib

News List

First bronchiectasis patient dosed in Phase III trial to study brensocatib europeanpharmaceuticalreview
December 04, 2020
The first patient with bronchiectasis has been dosed in the Phase III ASPEN study of brensocatib, a reversible inhibitor of dipeptidyl peptidase 1.
Insmed Receives FDA Breakthrough Therapy Designation for Non-Cystic Fibrosis Bronchiectasis Treatment americanpharmaceuticalreview
June 17, 2020
Insmed announced the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation for brensocatib (formerly known as INS1007) for the treatment of adult patients with non-cystic fibrosis bronchiectasis (NCFBE) for reducing ...